MeSH D013290 - streptococcal infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D016908:Gram-positive bacterial infections
D013290:Â
Streptococcal infections
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| A.H. Robins Company | Erythromycin lactobionate | Erythromycin |  | 1985-03-28 |  |  |
| Erythromycin | Robimycin |  | 1982-01-01 |  |  | |
| Abbott Biotherapeutics | Clindamycin | Clindamycin |  | 2001-06-29 |  |  |
| Erythromycin lactobionate | Erythrocin |  | 1988-01-04 |  |  | |
| Alembic Pharmaceuticals | Clindamycin | Clindamycin |  | 2024-04-02 |  |  |
| Linezolid | Linezolid |  | 2015-12-21 |  |  | |
| Erythromycin | Erythromycin |  | 2023-08-24 |  |  | |
| Alkem Laboratories | Linezolid | Linezolid |  | 2015-12-21 |  |  |
| Erythromycin | Erythromycin |  | 2022-07-13 |  |  |
1
2
3
4
5
6
...
18
>
Clinical Trials
Historical Success Rate
Phase 1
67%2/3
Phase 2
0%0/6
Phase 3
100%62/62
Approved: 60Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
12
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use